Interferon γ and antisense transforming growth factor β transgenes synergize to enhance the immunogenicity of a murine mammary carcinoma

Cancer Immunology Immunotherapy

Volumn 48, Issue 2-3, 1999, Pages 63-70

  McEarchern, Julie A ^a   Besselsen, David G ^a   Akporiaye, Emmanuel T ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Antisense TGF ; IFN ; Immunogenicity; Immunosuppression; Mammary carcinoma

Indexed keywords

GAMMA INTERFERON; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CARCINOGENESIS; CELL LINE; DRUG POTENTIATION; FEMALE; GENE EXPRESSION; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE;

ANIMALS; ANTISENSE ELEMENTS (GENETICS); CD8-POSITIVE T-LYMPHOCYTES; FEMALE; INTERFERON TYPE II; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TRANSFORMING GROWTH FACTOR BETA; TRANSGENES;

EID: 0032994017     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050549     Document Type: Article

References (25)

1. Armstrong TD, Clements VK, Martin BK, Ting J P-Y, Ostrand-Rosenberg S (1997) Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad SCi USA 94:6886-6891
2. + T lymphocytes. J Immunol 160:661-666
3. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT (1993) Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression. Clin Invest 92:2569-2576
4. Carlsson G, Gullberg B, Hafstrom L (1983) Estimation of liver tumor volume using different formulas - an experimental study in rats. J Cancer Res Clin Oncol 105:20-23
5. Czarniecki CW, Chiu HH, Wong GHW, McCabe SM, Palladino MA (1988) Transforming growth factor-β1 modulates the expression of class II histocompatibility antigens on human cells. J Immunol 140:4217-4223
6. Dranoff G, Mulligan RC (1995) Gene transfer as cancer therapy. Adv Immunol 58:417-454
7. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE (1996) Eradication of established intracranial rat gliomas by transforming growth factor βanti-sense gene therapy. Proc Natl Acad Sci USA 93:2909-2914
8. Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, Jarnicki AG, Marzo AL, Robinson BWS (1994) Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors 11:29-44
9. Fynan TM, Reiss M (1993) Resistance to inhibition of cell growth by transforming factor-beta and its role in oncogenesis. Crit Rev Oncog 4:493-540
10. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H (1994) Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961-965
11. Huang AYC, Bruce AT, Pardoll DM, Levitsky HI (1996) Does B7-1 Expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 183:769-776
12. Jachimczak P, Bogdahn U, Schneider J, Behl C, Meixensberger J, Apfel R, Dorries R, Schlingensiepen K-H, Brysch W (1993) The effect of transforming growth factor-β2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg 78:944-951
13. Marzo AL, Fitzpatrick DR, Robinson BWS, Scott B (1997) Antisense oligonucleotides specific for transforming growth factor β2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 57:3200-3207
14. McAdam A, Felcher A, Woods ML, Pulaski BA, Hutter EK, Frelinger JG, Lord EM (1994) Transfection of transforming growth factor-β producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytotoxic T-lymphocytes. J Immunother 15:155-164
15. Miyazono K, Ten Dijke P, Ichijo H, Heldin C-H (1994) Receptors for transforming growth factor-β. Adv Immunol 55:181-220
16. Mule JJ, Schwarz SL, Roberts AB, Sporn MB, Rosenberg SA (1988) Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunol Immunother 26:95-100
17. Panelli MC, Wang E, Shen S, Schluter SF, Bernstein RM, Hersh E, Stopeck A, Gangavalli R, Barber J, Jolly D, Akporiaye ET (1996) Interferon γ (IFNγ) gene transfer of an EMT6 tumor that is poorly responsive to IFNy stimulation: increase in tumor immunogenicity is accompanied by induction of a mouse class II transactivator and class II MHC. Cancer Immunol Immunother 42:99-107
18. Park JA, Wang E, Kurt RA, Schluter SF, Hersh EM, Akporiaye ET (1997) Expression of an antisense transforming growth factor-β1 transgene reduces tumorigenicity of EMT6 mammary tumor cells. Cancer Gene Ther 4:42-50
19. Rock KL (1996) A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 17:131-137
20. Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB, Lane HC, Fauci AS (1986) Effects of transforming growth factor β on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 136:3916-3920
21. Tada T, Ohzeki S, Utsumi K, Takiuchi H, Muramatsu M, Li X-F, Shimizu J, Fujiwara H, Hamaoka T (1991) Transforming growth factor-β-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 146:1077-1082
22. Takeuchi M, Kosiewicz MM, Alard P, Streilein JW (1997) On the mechanisms by which transforming growth factor-β2 alters antigen-presenting abilities of macrophages on T cell activation. Eur J Immunol 27:1648-1656
23. Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA (1990) A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 87:1486-1490
24. + T cells by B7-transfected melanoma cells. Science 259:368-370
25. Wojtowicz-Praga S (1997) Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother 20:165-177